Hematology Advisor

29/07/2024

The safety and feasibility of a CD22-targeted CAR T-cell therapy after large B-cell progression after receiving CD19 CAR-T therapy was demonstrated in a phase 1 trial. Published in The Lancet.

Researchers determined the safety and feasibility of a CD22-targeted CAR-T therapy after LBCL progression after receiving CD19 CAR-T therapy.

28/07/2024

An increase in oxidative metabolism triggers intracellular fumarate accumulation in mesenchymal stromal cells in and drives cellular senescence and the onset of fibrosis. From Rare Disease Advisor.

The expression of genes associated with senescence increased in the mesenchymal stromal cells after fumarate exposure.

27/07/2024

The implementation of MRD assessment based on next generation sequencing could improve prognostic accuracy in acute . From Rare Disease Advisor.

In patients with bone marrow relapse, there was evidence of elevated MRD on NGS before morphologic changes were observed.

26/07/2024

Patients with chronic or who underwent IgG testing and treated if found to have hypogammaglobulinemia demonstrated lower rates of infections and antimicrobial use. Published in American Society of Hematology journal Blood Advances.

Researchers determined patients with CLL and NHL who underwent IgG testing and treated if found to have hypogammaglobulinemia demonstrated lower rates of infections and antimicrobial use.

26/07/2024

The researchers considered the model to show high accuracy in assessing response and high sensitivity in identifying patients with who had a high risk of death.

Researchers determined an AI-based algorithm for radiologic response assessment was similar to that observed through the assessments of medical experts for NHL.

24/07/2024

Class of genetic variant was identified as a predictive biomarker for disease severity and survival in Wiskott-Aldrich syndrome in a study reported in the journal Blood (American Society of Hematology).

Class of genetic variant was identified as a predictive biomarker for disease severity and survival in Wiskott-Aldrich syndrome.

23/07/2024

Among previously untreated or minimally treated infants with severe , appears to be both safe and effective, according to research presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress.

Researchers determined emicizumab appears to be safe and effective in previously untreated or minimally treated infants with severe hemophilia A.

22/07/2024

TU7710, a long-acting recombinant activated factor VIIa developed by TiumBio to treat hemophilia, showed an extended half-life compared with the recombinant human coagulation factor VIIa NovoSeven® RT, a conventional hemophilia treatment.

Further advancements are anticipated soon, with the company planning to initiate a phase 1b clinical trial of TU7710 for hemophilia patients in Europe.

22/07/2024

The combined use of a CD45-targed ADC to deplete HSC, followed by transplantation with HSCs engineered to be shielded from the ADC may represent a novel approach to treat . Published in Nature Portfolio.

Researchers demonstrated that CIM053-SG3376 depleted CD45-positive cells in mouse models.

21/07/2024

Infants born between May and September are at increased risk for -associated , whereas those born between October and December are at increased risk for RSV-related hospitalization. Published in the Oxford Academic (Oxford University Press) Journal of the Pediatric Infectious Diseases Society and Infectious Disease Advisor.

Infants born between May and September exhibited the highest risk for medically attended RSV-associated LRTI during their first RSV season.

20/07/2024

due to C1 inhibitor protein deficiency is associated with an increased risk of venous thromboembolism, positioning as a rare thrombophilia. Published in American Society of Hematology journal Blood and Rare Disease Advisor.

The risk of developing VTE is high in young and middle-aged adults with HAE and is independent of treatment.

19/07/2024

The addition of venetoclax to agents such as BTK inhibitors and chemoimmunotherapy resulted in response rates that were higher than historical studies among patients with Richter transformation chronic . Published in American Society of Hematology journal Blood Advances.

Venetoclax-based combination therapies resulted in response rates that were higher than historical studies among patients with Richter transformation CLL.

18/07/2024

The U.S. Food and Drug Administration has approved Blincyto® (blinatumomab) for the treatment of adult and pediatric patients 1 month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute in the consolidation phase of multiphase chemotherapy. From MPR - Medical Professionals Reference.

Blincyto is approved for patients with CD19-positive Philadelphia chromosome-negative B-cell precursor ALL in the consolidation phase.

17/07/2024

The U.S. Food and Drug Administration has granted accelerated approval to Epkinly® (epcoritamab-bysp) for the treatment of adults with R/R after 2 or more lines of systemic therapy.

Accelerated approval to Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma.

16/07/2024

Researchers devised a new risk stratification model for prognosis in patients with active . Reported in the American Society of Clinical Oncology Journal of Clinical Oncology.

Researchers developed a new risk stratification model for prognosis in patients with active Waldenström macroglobulinemia.

15/07/2024

During the wars in Iraq and Afghanistan, injured US military service members had greater odds of having received prescription 30 days before the date of injury than uninjured controls. From Clinical Pain Advisor.

During the wars in Iraq and Afghanistan, injured US military service members had greater odds of having received prescription opioids 30 days before the date of injury than uninjured controls.

14/07/2024

Few CCCP plans from the CDC directly addressed . These findings were published as a Research Letter in JAMA Oncology and Oncology Nurse Advisor.

NCI investigators reviewed 65 comprehensive cancer control plans to determine whether and how the plans are addressing the effects of climate change. Most National Comprehensive Cancer Control Programs are not addressing cancer care access and cancer risk issues related to climate change.

13/07/2024

Treatment with adalimumab was associated with improvement in common hematologic abnormalities in patients with regardless of their HiSCR status. Published in JAMA Dermatology and Dermatology Advisor.

Patients with HS treated with adalimumab had significant improvement in hemoglobin levels, platelet count, and WBC count.

12/07/2024

Nonmyeloablative haploidentical BMT with thiotepa and PTCy is a widely available curative option for adult patients with . Published in American Society of Hematology journal Blood.

Researchers determined BMT with posttransplant cyclophosphamide and thiotepa is a curative option for adult patients with SCD.

11/07/2024

The use of circulating tumor DNA appeared to have prognostic value in assessing patients with R/R undergoing treatment in an analysis reported in the ScienceDirect journal Blood.

Researchers determined use of ctDNA appeared to have prognostic value in assessing patients with relapsed/refractory multiple myeloma undergoing treatment.

10/07/2024

Treatment of juvenile myelomonocytic with trametinib demonstrated promising response rates in a small phase 2 trial conducted by the Children’s Oncology Group. Published in the American Association for Cancer Research (AACR) journal Cancer Discovery.

Researchers determined trametinib may be an effective treatment option for patients with JMML.

09/07/2024

Region-specific guidelines for management of in Kuwait, Oman, Qatar, and the United Arab Emirates were recently developed by an expert panel including members of Gulf Cooperation Council countries. Reported in American Society of Clinical Oncology journal JCO Global Oncology.

An expert panel with the GCC developed region-specific guidelines for AML care for patients in Kuwait, Oman, Qatar, and the United Arab Emirates.

08/07/2024

Fitusiran prophylaxis appeared to show efficacy and be well tolerated in a study evaluating its use in people with A or B who had been switched from the use of BPA/CFC prophylaxis. Study results were reported in the American Society of Hematology journal Blood.

http://lite.spr.ly/6004B3ve

08/07/2024

Today is the LAST DAY you can shop our 4th of July sale with up to 25% off all premium courses for every specialty and medical profession. 🎉 Don't miss out – shop now! ➡️ https://www.mycme.com/pages/cme-offers

07/07/2024

High failure rates in late-stage clinical development of treatments suggest a need for better early-stage predictive models. Published in American Society of Hematology journal Blood Advances.

https://bit.ly/45MlBm5

Researchers sought to provide insights into the crossroads of orphan drug designations and regulations in SCD.

06/07/2024

For patients with , gaps in care during the transfer from pediatric to adult care appeared to increase acute health care resource utilization in a study published in American Society of Hematology journal Blood Advances.

Researchers determined gaps in care during the transfer from pediatric to adult SCD care appeared to increase acute health care resource utilization.

05/07/2024

The U.S. Food and Drug Administration has approved Piasky (crovalimab-akkz) for the treatment of adult and pediatric patients 13 years of age and older with weighing at least 40kg. From MPR - Medical Professionals Reference.

Piasky approved for the treatment of adult and pediatric patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria weighing at least 40kg.

04/07/2024

Treatment with was associated with a significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in patients with with . From MPR - Medical Professionals Reference.

Vutrisiran was associated with a significant reduction in the composite of all-cause mortality and recurrent CV events in ATTR with cardiomyopathy.

04/07/2024

🌟Light up your 4th of July with savings!🌟Get up to 25% off premium courses, including BoardVitals question banks, NPACE pharmacology bundles, Rutgers School of Health Professions PANCE/PANRE reviews, and more. Elevate your learning journey today!

https://brnw.ch/21wL7FJ

03/07/2024

A real-world study based in Italy suggests the use of caplacizumab has provided benefits for patients with immune-mediated . Reported in the MDPI Journal of Clinical Medicine.

Researchers determined caplacizumab has provided benefits for patients with iTTP.